Date: 23-Jul-2019

Boehringer enriches cancer immunology portfolio with AMAL Therapeutics acquisition

AMALs lead vaccine ATP128 is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month, and Boehringer Ingelheim plans to develop new therapies by combining assets from its cancer immunology portfolio with AMALs proprietary KISIMA immunisation platform. “Acquiring AMAL is part of Boehringer Ingelheim’s long-term strategy to enhance our existing position as an innovator of novel cancer therapies, including immuno-oncology treatments, which leverage cutting-edge scientific discoveries and their applications,” said Michel Pairet, member of Boehringer Ingelheims board of managing directors.